Consultiva Wealth Management’s Moderna MRNA Stock Holding History

Consultiva Wealth Management’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$35K	Hold	500	–	–	0.08%	135
2026 Q1	$25.4K	Hold	500	–	–	0.07%	142
2025 Q4	$14.7K	Hold	500	–	–	0.04%	180
2025 Q3	$12.9K	Hold	500	–	–	0.04%	190
2025 Q2	$13.8K	Hold	500	–	–	0.04%	194
2025 Q1	$14.2K	Buy	+500	New	+$17.7K	0.05%	186
2024 Q4	–	Sell	-475	Closed	-$31.7K	–	165
2024 Q3	$31.7K	Hold	475	–	–	0.25%	18
2024 Q2	$56.4K	Hold	475	–	–	0.51%	15
2024 Q1	$50.6K	Buy	+475	New	+$47.9K	0.47%	13
2023 Q3	$49.1K	Hold	475	–	–	1.26%	12
2023 Q2	$57.7K	Hold	475	–	–	1.46%	10
2023 Q1	$73K	Hold	475	–	–	1.87%	9
2022 Q4	$85.3K	Hold	475	–	–	2.22%	9
2022 Q3	$56K	Hold	475	–	–	1.57%	10
2022 Q2	$68K	Hold	475	–	–	1.91%	11
2022 Q1	$82K	Hold	475	–	–	1.97%	11
2021 Q4	$121K	Hold	475	–	–	2.76%	9
2021 Q3	$183K	Buy	+475	New	+$175K	4.21%	4
2021 Q1	$62K	Hold	475	–	–	1.35%	17
2020 Q4	$50K	Buy	+475	New	+$48.1K	1.17%	19
2019 Q2	$112K	Buy	+475	New	+$10.2K	2.28%	10

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Consultiva Wealth Management's MRNA Position: Q2 2026 in Review

Consultiva Wealth Management held its Moderna (MRNA) position steady in Q2 2026 at 500 shares worth $35K. The position accounts for 0.08% of the portfolio, ranked #135.

Consultiva Wealth Management first reported a position in MRNA in Q2 2019 and has held it in 21 quarters since. The position peaked at $183K in Q3 2021. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

Consultiva Wealth Management held 500 shares of Moderna worth $35K as of Q2 2026.
Consultiva Wealth Management left its Moderna share count unchanged in Q2 2026.
Moderna made up 0.08% of Consultiva Wealth Management's portfolio in Q2 2026, its #135 holding.
Consultiva Wealth Management first reported a position in Moderna in Q2 2019 and has held it in 21 quarters since.
Consultiva Wealth Management's Moderna position peaked at $183K in Q3 2021.
782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Consultiva Wealth Management's 13F filing for Q2 2026, filed 13 Aug 2026.